Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + clonazepam
- Development stage
- Unknown
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**escitalopram + clonazepam** is a fixed-dose combination of two drugs: **escitalopram**, a selective serotonin reuptake inhibitor (SSRI) used primarily as an antidepressant, and **clonazepam**, a benzodiazepine that acts as an anticonvulsant, muscle relaxant, and anxiolytic. This combination is indicated for the treatment of anxiety disorders, often prescribed when monotherapy does not sufficiently control symptoms. **Escitalopram** acts by selectively inhibiting serotonin reuptake, increasing serotonin levels in the synaptic cleft, and its clinical activity is mediated via the serotonin transporter. **Clonazepam** works by potentiating GABAergic neurotransmission through positive allosteric modulation of GABA-A receptors, resulting in decreased neuronal excitability and providing a calming effect. The combination targets both mood and anxiety symptoms, with clonazepam providing more rapid anxiolytic and sedative effects while escitalopram's antidepressant effect emerges more gradually[1][2][4][7].
- Brand names
- Nexito PlusStalopam PlusNexito ForteSzetalo PlusFeliz S PlusStalopamDepranClonafit PlusNexito LSNewcita PlusEcentopam Plus
- Other names
- escitalopram + clonazepamescitalopram oxalate + clonazepam
02
Targets
SERT (Sodium-dependent serotonin transporter)HTR3A (5-hydroxytryptamine receptor 3A)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on escitalopram + clonazepam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + clonazepam.